Concord Biotech Limited vs Syngene International Limited
Last updated: 25 October 2026
Concord Biotech vs Syngene International: A MoneyDock Comparison
In the dynamic Indian pharmaceutical and life sciences sector, investors often look for companies with strong growth potential and resilient business models. This comparison focuses on two distinct players: Concord Biotech Limited and Syngene International Limited. Concord Biotech is known for its biopharmaceutical products, particularly fermentation-based APIs (Active Pharmaceutical Ingredients) and formulations. Syngene International, on the other hand, is a leading contract research, development, and manufacturing organization (CRDMO) providing services to pharmaceutical, biotechnology, nutrition, animal health, and consumer goods companies globally. Both operate in critical segments of the healthcare value chain, making a direct comparison of their recent market performance and stability metrics valuable for investors.
Key Financial Metrics Comparison
| Metric | Concord Biotech Limited | Syngene International Limited |
|---|---|---|
| Current Price | ₹1229.30 | ₹366.85 |
| 52-Week High | ₹1579.40 | ₹659.00 |
| 52-Week Low | ₹1014.80 | ₹346.00 |
| 1-Year Return | -7.65% | -43.26% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Valuation, Returns, and Stability
Valuation: With both companies showing 'N/A' for Trailing P/E and Market Cap in the provided data, a direct valuation comparison using these metrics is not possible. Investors would need more comprehensive financial statements to assess their intrinsic value relative to their current prices. However, looking at the current price relative to their 52-week highs, Concord Biotech is trading about 22% below its high (₹1229.30 vs ₹1579.40), while Syngene International is significantly further down, trading about 44% below its high (₹366.85 vs ₹659.00). This suggests that Syngene might appear 'cheaper' relative to its recent peak, but without profitability metrics, it's hard to confirm.
Returns: On the returns front, Concord Biotech Limited clearly outperforms Syngene International Limited over the past year. Concord Biotech recorded a 1-Year Return of -7.65%, which, while negative, is considerably better than Syngene International's -43.26%. This indicates that Concord Biotech has demonstrated greater resilience or faced fewer headwinds in the last twelve months compared to Syngene.
Stability: Stability can be inferred by looking at the proximity of the current price to the 52-week low. Concord Biotech's current price of ₹1229.30 is about 21% above its 52-week low of ₹1014.80. Syngene International's current price of ₹366.85 is quite close to its 52-week low of ₹346.00, only about 6% above it. This suggests that Syngene is currently trading near the lower end of its annual price range, potentially indicating higher volatility or persistent selling pressure, thus appearing less stable in its recent performance compared to Concord Biotech.
MoneyDock Verdict
For Aggressive Investors: Syngene International, trading significantly below its 52-week high and near its 52-week low, might present a contrarian opportunity if one believes the underlying business challenges are temporary and a strong rebound is imminent. The higher risk comes with potentially higher rewards if the turnaround materializes.
For Conservative Investors: Concord Biotech appears to be the more stable choice based on the provided metrics. Its significantly better 1-Year Return and greater distance from its 52-week low suggest less volatility and more resilience in the current market environment. It could be a preferred option for those prioritizing capital preservation.
For Long-Term SIP Investors: Given the current data, Concord Biotech seems more appealing due to its relatively stronger short-term performance and stability. However, for a truly diversified long-term SIP, investors might consider staggering investments in both if a deeper fundamental analysis reveals strong long-term prospects for Syngene despite its current dip. Without P/E ratios and market cap, a definitive long-term valuation is challenging, but Concord's current performance indicates a potentially smoother ride.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.